Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System

Status Completed

Clinical Trial Summary

The objective is to establish that APTIMA HPV Assay performance on the PANTHER System is comparable to performance on the TIGRIS System.

Clinical Trial Description

The APTIMA HPV Assay is an in vitro nucleic acid amplification test for the qualitative detection of E6/E7 viral messenger RNA (mRNA) from 14 high-risk types of human papillomavirus (HPV) in cervical specimens. The high-risk HPV types detected by the assay include: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The APTIMA HPV Assay does not discriminate between the 14 high-risk types. Cervical specimens collected in ThinPrep Pap Test vials containing PreservCyt® Solution with commercially available collection devices (broom-type device or cytobrush/spatula combination) may be tested with the APTIMA HPV Assay either pre- or post-Pap processing. The assay is used with the TIGRIS System and the PANTHER System.

The objective is to establish that APTIMA HPV Assay performance on the PANTHER System is comparable to performance on the TIGRIS System. ;

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01446198
Study type	Observational
Source	Gen-Probe, Incorporated
Contact
Status	Completed
Phase	N/A
Start date	March 2012
Completion date	May 2012

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04199078` - Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.	N/A
Active, not recruiting	`NCT02135419` - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions	Phase 3
Active, not recruiting	`NCT02258659` - Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer	Phase 2
Completed	`NCT02714114` - Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study)	N/A
Completed	`NCT00303823` - Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia	Phase 2
Not yet recruiting	`NCT05510830` - Diagnostic Cervical Conization for Persistent Infection or Integration of HPV	N/A
Completed	`NCT04002154` - Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV	N/A
Not yet recruiting	`NCT06123533` - Understanding Women's Values in Managing Human Papillomavirus (HPV)
Completed	`NCT04624568` - Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance	N/A
Completed	`NCT05694728` - A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine	Phase 2
Completed	`NCT04391647` - Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples
Recruiting	`NCT05439083` - Immunogenicity of 9-valent HPV Vaccine	Phase 4
Completed	`NCT01539668` - Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas	Phase 0
Completed	`NCT01567813` - Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)
Completed	`NCT02811367` - The HPV Self-test as a Test of Cure in Madagascar	N/A
Completed	`NCT02067507` - Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County	N/A
Recruiting	`NCT01387997` - e- Ab Sensor-based Real-time Detection of Oncogenic Human Papilloma Viruses	N/A
Completed	`NCT02634190` - Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens
Completed	`NCT00054041` - Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia	Phase 2
Active, not recruiting	`NCT01898494` - Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer	Phase 2